The SERENA-2 trial (NCT04214288) is a randomised, multicentre phase II trial evaluating camizestrant at several dose levels compared to fulvestrant in advanced ER-positive, HER2-negative breast cancer. In this touchONCOLOGY interview, we speak with Dr Mafalda Oliveira (Vall d’Hebron University Hospital Barcelona, Spain) who gives an overview of the SERENA-2 trial and the advantages for the use of camizestrant over fulvestrant as well as discussing the next steps in the clinical development of camizestrant.
The abstract entitled ‘Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
- What is camizestrant and what are its potential advantages over fulvestrant in the treatment of post-menopausal women with advanced ER-positive HER2-negative breast cancer? (0:18)
- What were the aims, design and eligibility criteria of the SERENA-2 trial? (1:18)
- What was the primary endpoint and how well was it achieved across the pre-specified subgroups of urgent medical need? (2:39)
- What were the safety and tolerability findings? (4:43)
- What will be the next steps in the clinical development of camizestrant? (5:43)
Disclosures: Mafalda Oliveira is a consultant for AstraZeneca, GuardantHealth, Roche, MSD, Relay Therapeutics, Pfizer, SeaGen, iTEOS and Gilead and discloses grant/research support from AstraZeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Genentech, GSK, Novartis, PUMA Biotechnology, Roche, SeaGen and Zenith Epigenetics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
Share this Video
Related Videos In Breast Cancer
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, EMSO 2023
Significant advancements in breast cancer research emerged from EMSO this year. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) […]
Trastuzumab duocarmazine in HER2+ metastatic breast cancer – TULIP trial results: Philippe Aftimos, ESMO 2023
The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician’s choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023. Dr. Philippe Aftimos, the study investigator from the Institute Jules Bordet in Belgium, presented the results at the conference and then discussed them […]
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!